DEA Proposes New Reporting Requirements for Controlled Substance Quotas

The Drug Enforcement Administration has proposed a rule that would change how drug manufacturers apply for annual quotas to make or buy controlled substances. Under the proposal, manufacturers would have to submit their expected production schedules for the coming year as part of their quota applications. They would also need to clearly separate the amount of material they plan to use for the U.S. market from the amount intended for export.

Why it matters: The practical effect of this proposal is mostly administrative. It would require manufacturers to provide more detailed paperwork when applying for their annual allowances of controlled substances. If finalized, the changes would help the DEA track how much of these substances is actually available for domestic medical and industrial use versus export, and could allow the agency to shift quota limits faster if a shortage develops. The impact on patients or the general public would be indirect, depending on whether the DEA uses the new data to prevent supply gaps.

Who it affects

• Registered bulk manufacturers of Schedule I and II controlled substances and List I chemicals

---

This notice comes from the Drug Enforcement Administration in the Federal Register; readers should check the original document and the regulations.gov docket for the full text and comment deadlines before relying on this summary.

Agency: Justice Department, Drug Enforcement Administration
Source: Federal Register — read the official document